Iaso Therapeutics, Inc.

Startup

Iaso has developed a novel self-assembled mutant Qβ (mQβ) bacteriophage capsid protein. The mQβ platform is an exciting new carrier for conjugate vaccines, providing an attractive alternative to current carriers. Also, mQβ carriers are associated with reduced antibody generation against the carrier while retaining the ability to elicit high levels of anti-antigen IgG antibodies compared to wild type Qβ. In head-to-head comparison studies, mQβ can induce a 3-10-fold higher IgG antibody titer when compared to CRM‑197 or keyhole limpet hemocyanin (KLH), respectively. Both are benchmark carrier proteins commonly utilized as a carrier moieties in vaccine studies. The mQβ carriers are a platform technology suitable for developing various vaccines.

Feature	Advantage	Benefit
Non-Toxic	The carrier itself does not need to be altered to be non-toxic	Ease of manufacturing
Ease of manufacturing	Simple bacterial fermentation	No expensive purifications
Uniformity of Carrier	Ease of manufacturing	Higher yield in fermentation because you do not have to purify away from related products.
Ab Titer Generated	Higher antibody titers compared to other carrier proteins	Do not need to have booster injections as often
Ability to generate mutants	Optimize antigen presentation to the immune system	Higher IgG production
Self-Adjuvant	Not necessary to add adjuvant	Higher IgG production
Persistent Antigen-specific Ab titers	Not necessary to boost injection as often	Fewer injections Low Ab production to carrier
It can be stored at R.T. as a lyophilized powder	Very stable product	No need to store it in Freezer

Iaso Therapeutics, Inc.

Startup

Created by